189 related articles for article (PubMed ID: 30231398)
1. What Will We Expect From Novel Therapies to Esophageal and Gastric Malignancies?
De Mello RA; Castelo-Branco L; Castelo-Branco P; Pozza DH; Vermeulen L; Palacio S; Salzberg M; Lockhart AC
Am Soc Clin Oncol Educ Book; 2018 May; 38():249-261. PubMed ID: 30231398
[TBL] [Abstract][Full Text] [Related]
2. From Tumor Immunology to Immunotherapy in Gastric and Esophageal Cancer.
Vrána D; Matzenauer M; Neoral Č; Aujeský R; Vrba R; Melichar B; Rušarová N; Bartoušková M; Jankowski J
Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30577521
[TBL] [Abstract][Full Text] [Related]
3. Beyond the PD-L1 horizon: In search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma.
Koemans WJ; Chalabi M; van Sandick JW; van Dieren JM; Kodach LL
Cancer Lett; 2019 Feb; 442():279-286. PubMed ID: 30419350
[TBL] [Abstract][Full Text] [Related]
4. Gastric Carcinomas With Lymphoid Stroma: An Evaluation of the Histopathologic and Molecular Features.
Hissong E; Ramrattan G; Zhang P; Zhou XK; Young G; Klimstra DS; Shia J; Fernandes H; Yantiss RK
Am J Surg Pathol; 2018 Apr; 42(4):453-462. PubMed ID: 29438172
[TBL] [Abstract][Full Text] [Related]
5. What Therapeutic Biomarkers in Gastro-Esophageal Junction and Gastric Cancer Should a Pathologist Know About?
Kumarasinghe MP; Houghton D; Allanson BM; Price TJ
Surg Pathol Clin; 2023 Dec; 16(4):659-672. PubMed ID: 37863558
[TBL] [Abstract][Full Text] [Related]
6. Next-generation Sequencing in the Management of Gastric and Esophageal Cancers.
Rubinstein JC; Nicolson NG; Ahuja N
Surg Clin North Am; 2019 Jun; 99(3):511-527. PubMed ID: 31047039
[TBL] [Abstract][Full Text] [Related]
7. Predictive biomarkers along gastric cancer pathogenetic pathways.
Panarese I; De Vita F; Ronchi A; Romano M; Alfano R; Di Martino N; Zito Marino F; Ferraraccio F; Franco R
Expert Rev Anticancer Ther; 2017 May; 17(5):417-425. PubMed ID: 28277834
[TBL] [Abstract][Full Text] [Related]
8. Lymphocyte-rich gastric cancer: associations with Epstein-Barr virus, microsatellite instability, histology, and survival.
Grogg KL; Lohse CM; Pankratz VS; Halling KC; Smyrk TC
Mod Pathol; 2003 Jul; 16(7):641-51. PubMed ID: 12861059
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer.
Pereira MA; Ramos MFKP; Faraj SF; Dias AR; Yagi OK; Zilberstein B; Cecconello I; Alves VAF; de Mello ES; Ribeiro U
J Surg Oncol; 2018 Apr; 117(5):829-839. PubMed ID: 29534305
[TBL] [Abstract][Full Text] [Related]
10. Progress in the development of protein biomarkers of oesophageal and gastric cancers.
Coghlin C; Murray GI
Proteomics Clin Appl; 2016 Apr; 10(4):532-45. PubMed ID: 26582241
[TBL] [Abstract][Full Text] [Related]
11. Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability.
Ma C; Patel K; Singhi AD; Ren B; Zhu B; Shaikh F; Sun W
Am J Surg Pathol; 2016 Nov; 40(11):1496-1506. PubMed ID: 27465786
[TBL] [Abstract][Full Text] [Related]
12. Alterations of transforming growth factor-beta 1 receptor type II occur in ulcerative colitis-associated carcinomas, sporadic colorectal neoplasms, and esophageal carcinomas, but not in gastric neoplasms.
Souza RF; Garrigue-Antar L; Lei J; Yin J; Appel R; Vellucci VF; Zou TT; Zhou X; Wang S; Rhyu MG; Cymes K; Chan O; Park WS; Krasna MJ; Greenwald BD; Cottrell J; Abraham JM; Simms L; Leggett B; Young J; Harpaz N; Reiss M; Meltzer SJ
Hum Cell; 1996 Sep; 9(3):229-36. PubMed ID: 9183654
[TBL] [Abstract][Full Text] [Related]
13. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.
Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B
Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918
[TBL] [Abstract][Full Text] [Related]
14. What's New in Gastric and Esophageal Cancers.
Tanabe K
Ann Surg Oncol; 2016 Nov; 23(12):3773. PubMed ID: 27638669
[No Abstract] [Full Text] [Related]
15. Gastric cancer and concomitant renal cancer: a systematic immunohistochemical and molecular analysis.
Betge J; Pollheimer MJ; Schlemmer A; Hoefler G; Langner C
Oncol Rep; 2011 Sep; 26(3):567-75. PubMed ID: 21687951
[TBL] [Abstract][Full Text] [Related]
16. [Updates and interpretation on NCCN clinical practice guidelines for gastric cancer 2017 version 5].
Qiu H; Zhou Z
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Feb; 21(2):160-164. PubMed ID: 29492914
[TBL] [Abstract][Full Text] [Related]
17. Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer.
Janjigian YY; Sanchez-Vega F; Jonsson P; Chatila WK; Hechtman JF; Ku GY; Riches JC; Tuvy Y; Kundra R; Bouvier N; Vakiani E; Gao J; Heins ZJ; Gross BE; Kelsen DP; Zhang L; Strong VE; Schattner M; Gerdes H; Coit DG; Bains M; Stadler ZK; Rusch VW; Jones DR; Molena D; Shia J; Robson ME; Capanu M; Middha S; Zehir A; Hyman DM; Scaltriti M; Ladanyi M; Rosen N; Ilson DH; Berger MF; Tang L; Taylor BS; Solit DB; Schultz N
Cancer Discov; 2018 Jan; 8(1):49-58. PubMed ID: 29122777
[TBL] [Abstract][Full Text] [Related]
18. Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches.
Ratti M; Lampis A; Hahne JC; Passalacqua R; Valeri N
Cell Mol Life Sci; 2018 Nov; 75(22):4151-4162. PubMed ID: 30173350
[TBL] [Abstract][Full Text] [Related]
19. Causes and consequences of microsatellite instability in gastric carcinogenesis.
Velho S; Fernandes MS; Leite M; Figueiredo C; Seruca R
World J Gastroenterol; 2014 Nov; 20(44):16433-42. PubMed ID: 25469011
[TBL] [Abstract][Full Text] [Related]
20. Current and Future Aspects of Immunotherapy for Esophageal and Gastric Malignancies.
De Mello RA; Lordick F; Muro K; Janjigian YY
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():237-247. PubMed ID: 31099644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
